Báo cáo trường hợp bệnh nhân dùng timolol 0,5% điều trị viêm quanh móng và dạng u hạt nhiễm khuẩn trên bệnh nhân sử dụng thuốc kháng EGFR

Abstract

Paronychia and pyogenic granuloma-like lesions are among the most noticeably undesirable side effects on patients treated with epidermal growth factor receptor inhibitor (EGFR). These badly affect the patients’ quality of life as well as their compliance with targeted therapies. There have been a number of treatments, with different chance of success, for this. Among the current strategies, high-potency topical corticosteroids are a well-known treatment option, especially for paronychia, targeting the inflammatory component of such lesions. However, managing pyogenic granuloma-like lesion is often more complicated. Nail plate avulsion and phenol chemical matricectomy are not highly effective and display some degree of invasiveness. Recently, topical β-blockers seem to be promising alternatives to treat patients with cancer who might be unsuitable candidates for an invasive procedure. This report centres on a clinical case of a patient receiving anti-EGFR monoclonal antibody therapy for his non small cell lung cancer and applying timolol 0.5% to his paronychia and pyogenic granuloma-like lesions twice a day. The patient recovered well after 8 weeks of treatment and there was no recurrence of lesions after 12 weeks.